Ernexa Therapeutics Inc. (NASDAQ:ERNA) Sees Significant Drop in Short Interest

Ernexa Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) was the recipient of a significant decrease in short interest in May. As of May 29th, there was short interest totaling 44,811 shares, a decrease of 72.4% from the May 14th total of 162,618 shares. Based on an average daily trading volume, of 99,259 shares, the days-to-cover ratio is presently 0.5 days. Currently, 3.9% of the company’s stock are sold short.

Analyst Ratings Changes

Several brokerages have issued reports on ERNA. Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. Brookline Capital Markets began coverage on Ernexa Therapeutics in a research note on Thursday, May 7th. They set a “buy” rating and a $30.00 price objective on the stock. Wall Street Zen cut Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Zacks Research upgraded Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Ernexa Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $30.00.

Get Ernexa Therapeutics alerts:

Read Our Latest Analysis on Ernexa Therapeutics

Ernexa Therapeutics Trading Up 3.3%

ERNA traded up $0.21 during trading hours on Thursday, hitting $6.55. The company’s stock had a trading volume of 22,634 shares, compared to its average volume of 951,818. Ernexa Therapeutics has a fifty-two week low of $3.18 and a fifty-two week high of $71.50. The firm has a market capitalization of $7.66 million, a PE ratio of -0.25 and a beta of 2.49. The company has a 50-day simple moving average of $7.43 and a 200 day simple moving average of $16.50.

Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($6.95) EPS for the quarter, missing the consensus estimate of ($1.95) by ($5.00). Research analysts expect that Ernexa Therapeutics will post -18.02 earnings per share for the current fiscal year.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 70.55% of the company’s stock.

About Ernexa Therapeutics

(Get Free Report)

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.

Featured Stories

• Five stocks we like better than Ernexa Therapeutics
• Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
• NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
• The World Cup Is Coming—These 3 Stocks Could Cash In
• Spotify’s “North Star” Outlook Was Music to Investors Ears

Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.